Sign up USA
Proactive Investors - Run By Investors For Investors

CytomX Therapeutics shoots higher as it's set for US$200mln upfront payment from Bristol-Myers Squibb

CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Cancerous cells
CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade

CytomX Therapeutics Inc (NASDAQ:CTMX) saw its shares shoot almost 25% higher in early New York trading after the biotech firm said it would receive a US$200mln upfront payment from drugs giant Bristol-Myers Squibb Co. (NYSE:BMY).

The payment is part of the expansion of a collaboration pact to discover cancer treatments using CytomX's Probody platform.

CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.

Bristol-Myers’ head of discovery, Carl Decicco, said: “CytomX's Probody platform has enhanced our discovery research as we seek to direct the therapeutic effects of immunotherapy in a more targeted approach against tumor.”

CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade.



Register here to be notified of future CTMX Company articles

Related Articles

genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Blood test
September 27 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use